Nurix Therapeutics, Inc. NRIX
15.30 USD +0.46 (+3.10%)
At closeNov 6, 2026, 5:55 PM EST
15.07 -0.23 -1.50%
After hours · Nov 6, 5:55 PM ET
14.79 Day range 15.52
12.17 52-week range 27.79
- YTD
- -19.35%
- 1 year
- +22.20%
News
globenewswire.com Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Crude Oil Down 5%; Uber Shares Jump After Q3 Results U.S. stocks rallied, led by the Dow and Nasdaq; Uber surged on revenue growth despite an earnings miss. Oil fell, while gold and silver climbed.
benzinga.com Wells Fargo Maintains Equal-Weight on Nurix Therapeutics, Lowers Price Target to $20 Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Equal-Weight and lowers the price target from $25 to $20.
benzinga.com Dow Jumps Over 1,100 Points; McDonald’s Shares Gain Following Upbeat Earnings U.S. stocks rallied, led by a 1,100-point Dow gain. McDonald’s rose on strong earnings; oil fell 3%, while gold and silver climbed.
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Limbach surged 14.7% after beating Q3 estimates and raising FY26 sales guidance; Curis gained 69.5%, while Cenntro plunged 46.5%.
benzinga.com Nurix Therapeutics Announces That Sanofi Notified Co. Of Its Decision To Discontinue The Phase 1 First-In-Human Clinical Trial Of SAR448272, And To Terminate The SAR448272 Program Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…
globenewswire.com Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272 BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today…
benzinga.com SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.
benzinga.com HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36 HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
benzinga.com RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35 RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.- benzinga.com Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32 Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.
- benzinga.com Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33 Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.
- benzinga.com Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36 Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
- benzinga.com CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.
benzinga.com Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of…- benzinga.com Nurix Gets $10M As Gilead Extends Drug Discovery Deal Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…
benzinga.com RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36 RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
benzinga.com Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…
benzinga.com Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38 Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.- benzinga.com UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31 UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.
- benzinga.com Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60% Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
- benzinga.com Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
- benzinga.com Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up…
- benzinga.com Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34 Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $34.
- benzinga.com Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34 Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
- benzinga.com RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33 RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $33.
- benzinga.com Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40 Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $40.
- benzinga.com BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34 HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
- benzinga.com Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of…
benzinga.com Top 3 Health Care Stocks That May Keep You Up At Night In June Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
- benzinga.com Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33 Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $33.
benzinga.com Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today…- benzinga.com HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
benzinga.com Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32 Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.
benzinga.com Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research…- benzinga.com BTIG Maintains Buy on Nurix Therapeutics, Raises Price Target to $32 BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.
- benzinga.com Jefferies Maintains Buy on Nurix Therapeutics, Raises Price Target to $45 Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $41 to $45.
- benzinga.com Needham Maintains Buy on Nurix Therapeutics, Raises Price Target to $34 Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $26 to $34.
benzinga.com Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell…- benzinga.com Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential…